There are no major contraindications identified with GHK-Cu, and it is considered safe for extended use
The STEP 1 trial used 2.4 mg as the target maintenance dose and achieved average weight loss of 14.9% of body weight over 68 weeks
Freeze aliquots not being used immediately
Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network Open (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Journal of Medicine (2021) Carnitine, National Institutes of Health (2023) Effects of three treatment modalities (diet, myoinositol, or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome, European Review for Medical and Pharmacological Sciences (2019) Who can perform semaglutide treatments?, American Med Spa Association (2023) Using fat-dissolving injections that are not FDA-approved can be harmful, U.S
It has been studied for its potential role in: Copper is important for connective tissue formation, antioxidant defense, and cellular function
DSIP Reported Research-Context Dose Ranges Pattern Older human trials Typical Range 25 nmol/kg Route IV Notes Short 4-7 night courses